

Multiple Sclerosis (MS)

**A Study To Investigate The Pharmacokinetics, Safety, And
Tolerability Of Subcutaneous Ocrelizumab Administration In Patients
With Multiple Sclerosis**

Trial Status
Active, not recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT03972306 CN41144

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03972306 CN41144
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 65 Years

Healthy Volunteers
No
